Filtered By:
Infectious Disease: Herpes
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 364 results found since Jan 2013.
Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections
CONCLUSION: Our data point to long-term abnormalities in the S1P signaling system as a biomarker for previous disseminated viral diseases and a potential treatment target in recurring infections.PMID:35304160 | DOI:10.1016/j.jaci.2022.02.027
Source: Herpes - March 19, 2022 Category: Infectious Diseases Authors: Evgeny Berdyshev Elena Goleva Irina Bronova Anna S Bronoff Joanne E Streib Kathryn A Vang Brittany N Richers Patricia Taylor Lisa Beck Miguel Villarreal Keli Johnson Gloria David Mark K Slifka Jon Hanifin Donald Ym Leung Source Type: research
A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
Am J Epidemiol. 2022 Feb 12:kwac030. doi: 10.1093/aje/kwac030. Online ahead of print.ABSTRACTThe recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the U.S. in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome (GBS) after vaccination was identified post-approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the U.S. using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clu...
Source: Am J Epidemiol - February 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research
Acupuncture, Shingles, and Allergen Immunotherapy
Conclusions: Acupuncture is a minor trauma that can predispose a patient to reactivation of VZV and shingles in the setting of immune activation with allergen immunotherapy.PMID:34976278 | PMC:PMC8716517 | DOI:10.1089/acu.2020.1521
Source: Acupuncture in Medicine - January 3, 2022 Category: Complementary Medicine Authors: David McMahon Sushma Kadiyala Irene M Estores Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
M002 new-onset rosacea in a patient on dupilumab treatment for nasal polyposis
Dupilumab is a humanized monoclonal antibody that inhibits the interleukin-4 receptor (IL-4R α), thereby blocking IL-4 and IL-13 signaling of the Th2 pathway. Via Th2 blockade, Dupilumab decreases eosinophil recruitment, rendering it an effective treatment for nasal polyps caused by chronic accumulation of eosinophils in the paranasal sinus mucosa. Side effects reported during clinical tri als included conjunctivitis, injection site reactions, and herpes infections.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: J. Fortier, J. Justice, A. Debenedetto, L. Cuervo-Pardo Source Type: research
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Defects of the Innate Immune System and Related Immune Deficiencies
AbstractThe innate immune system is the host ’s first line of defense against pathogens. Toll-like receptors (TLRs) are pattern recognition receptors that mediate recognition of pathogen-associated molecular patterns. TLRs also activate signaling transduction pathways involved in host defense, inflammation, development, and the production of inflammatory cytokines. Innate immunodeficiencies associated with defective TLR signaling include mutations inNEMO,IKBA,MyD88, andIRAK4. Other innate immune defects have been associated with susceptibility to herpes simplex encephalitis, viral infections, and mycobacterial disease, a...
Source: Clinical Reviews in Allergy and Immunology - August 21, 2021 Category: Allergy & Immunology Source Type: research
Prolonged high-intensity exercise induces fluctuating immune responses to herpes simplex virus infection via glucocorticoids
We describe that prolonged high-intensity exercise leads to impaired or enhanced immune responses against HSV-2 infection depending on the timing between infection and exercise.
Source: Journal of Allergy and Clinical Immunology - May 6, 2021 Category: Allergy & Immunology Authors: Akimasa Adachi, Tetsuya Honda, Teruki Dainichi, Gyohei Egawa, Yosuke Yamamoto, Takashi Nomura, Saeko Nakajima, Atsushi Otsuka, Masamitsu Maekawa, Nariyasu Mano, Naoto Koyanagi, Yasushi Kawaguchi, Toshiaki Ohteki, Takashi Nagasawa, Koichi Ikuta, Akihiko Ki Source Type: research
Viral Infections and Cutaneous Drug-Related Eruptions
In the general population, up to 10% of children treated by antibiotics have cutaneous adverse drug reaction, but allergy is confirmed in less than 20% of patients. Most of the non-allergic reactions are probably due to virus, such as enterovirus acute infection or Ebstein-Barr Virus (EBV) acute infection or reactivation. Especially in children, viruses have the propensity to induce skin lesions (maculopapular rash, urticaria) due to their skin infiltration or immunologic response. In drug-related skin eruptions, a virus can participate by activating an immune predisposition. The culprit antibiotic is then the trigger for ...
Source: Frontiers in Pharmacology - March 10, 2021 Category: Drugs & Pharmacology Source Type: research
Clonal expansion of CD4+CD8+ T cells in an adult patient with Mycoplasma pneumoniae-associated Erythema multiforme majus
Erythema multiforme (EM) is an acute, immune-mediated mucocutaneous disease, most often preceded by herpes simplex virus (HSV) infection or reactivation. Mycoplasma pneumoniae (Mp) is considered the second major ...
Source: Allergy, Asthma and Clinical Immunology - February 10, 2021 Category: Allergy & Immunology Authors: Sarah M. Volkers, Christian Meisel, Dorothea Terhorst-Molawi, Guido J. Burbach, Dirk Sch ürmann, Norbert Suttorp and Leif E. Sander Tags: Case Report Source Type: research
Differential Contribution Of TNFSF14/LIGHT-Receptor Mediated Pathways To Inflammatory Fibroblast Phenotypes In Eosinophilic Esophagitis
Fibroblasts (FBL) mediate tissue remodeling in eosinophilic esophagitis (EoE), a chronic allergen driven inflammatory pathology. We recently defined a putative role of the cytokine TNFSF14/LIGHT as a promoter of an inflammatory esophageal FBL subtype. LIGHT can signal through two receptors, herpes virus entry mediator (HVEM) and lymphotoxin-beta receptor (LT ßR). We investigated the relative contributions of each receptor to LIGHT-mediated inflammatory FBL differentiation.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Mario Cabrero Manresa, Elaine Pham, Loan Duong, Haruka Miki, Michael Croft, Seema Aceves Source Type: research
